COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=49088

Jianfeng Zhou

zhougene@medmail.com.cn

2020-02-05

Recruiting

RCT

Randomized

Parallel

Blind label

single-center

Treatment

1. Aged >= 18 years and <= 75 years, 2. Patients clinically diagnosed as novel coronavirus infection, or with positive serum antibodies (IgM or IgG), or with novel coronavirus infection confirmed by PCR, 3. Severe/critical patients.

1. Patients with other malignant tumors requiring treatment, 2. Severe cardiovascular and metabolic diseases beyond the control of combination with other drugs 3. Patients with clinical symptoms of brain dysfunction or serious mental illness who cannot understand or follow the study protocol, 4. Endotracheal intubation with invasive ventilation, 5. Patients who cannot guarantee completion of necessary treatment plan and follow-up observation, 6. Women of child-bearing age who are positive in pregnancy test or do not stop breastfeeding in lactation period, 7. Patients with other infections at the time of enrollment, 8. Other circumstances that prevent the protocol from proceeding safely.

2

Department of Hematology; Tongji Hospital; Tongji Medical College; Huazhong University of Science and Technology

18

75

China

Severe/critical disease at enrollment

7: Severe/critical disease at enrollment

70

Safety;

| Declared number of arm (2.0) differs from found arms (3.0)

Phase 0

[{"arm_notes": "", "treatment_id": 1135, "treatment_name": "Ruxolitinib", "treatment_type": "Kinase inhibitors", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]